Antibacterial Activity of Silver Nanoparticles against Pseudomonas aeruginosa PAO1
Faculty Mentor
Dong Kwon
Major/Area of Research
Biology
Description
INTRODUCTION: Pseudomonas aeruginosa (P. aeruginosa) is a prevalent Gram-negative bacterium and a leading cause of healthcare-associated infections, particularly among immunocompromised patients. Its intrinsic and acquired resistance to multiple antibiotics significantly limits effective treatment options, highlighting the need for novel antimicrobial strategies. Silver nanoparticles (AgNPs) have emerged as a promising alternative due to their unique size-dependent properties and multiple mechanisms of action, including disruption of bacterial membranes and interference with cellular metabolism. This study investigates the antibacterial potential of four AgNP compounds against P. aeruginosa.
METHOD: The Minimum Bactericidal Concentration (MBC) assay was used to evaluate the bactericidal activity of four AgNP compounds (A, B, C, and D) across five serial dilutions (0.25-4 µg/mL). Overnight cultures of P. aeruginosa were exposed to each AgNP concentration and plated on Mueller-Hinton agar. Colony-forming units (CFU/mL) were quantified after incubation to determine the minimum concentration required to completely inhibit bacterial growth.
RESULTS: All compounds demonstrated concentration-dependent antibacterial activity. Compound B was the most effective, with an MBC of 0.5 µg/mL, followed by Compound C at 2 µg/mL, Compound D at 4 µg/mL, and Compound A, with an MBC exceeding 4 µg/mL. Positive control plates showed unrestricted bacterial growth, confirming that growth inhibition was due solely to the AgNP treatment.
DISCUSSION/CONCLUSION: The results confirm that AgNPs possess strong in vitro bactericidal activity against P. aeruginosa, with efficacy varying by compound. Compound B demonstrated the greatest potential as an antimicrobial agent. These findings support the use of silver nanoparticles as a non-antibiotic treatment for multidrug-resistant bacterial infections. Determining the MBC is crucial for guiding potential therapeutic applications, ensuring maximum efficacy while minimizing cytotoxicity. Future studies should examine the effects of particle size, shape, and surface chemistry on antibacterial activity, as well as evaluate AgNP efficacy in vivo to fully assess their clinical potential.
Antibacterial Activity of Silver Nanoparticles against Pseudomonas aeruginosa PAO1
INTRODUCTION: Pseudomonas aeruginosa (P. aeruginosa) is a prevalent Gram-negative bacterium and a leading cause of healthcare-associated infections, particularly among immunocompromised patients. Its intrinsic and acquired resistance to multiple antibiotics significantly limits effective treatment options, highlighting the need for novel antimicrobial strategies. Silver nanoparticles (AgNPs) have emerged as a promising alternative due to their unique size-dependent properties and multiple mechanisms of action, including disruption of bacterial membranes and interference with cellular metabolism. This study investigates the antibacterial potential of four AgNP compounds against P. aeruginosa.
METHOD: The Minimum Bactericidal Concentration (MBC) assay was used to evaluate the bactericidal activity of four AgNP compounds (A, B, C, and D) across five serial dilutions (0.25-4 µg/mL). Overnight cultures of P. aeruginosa were exposed to each AgNP concentration and plated on Mueller-Hinton agar. Colony-forming units (CFU/mL) were quantified after incubation to determine the minimum concentration required to completely inhibit bacterial growth.
RESULTS: All compounds demonstrated concentration-dependent antibacterial activity. Compound B was the most effective, with an MBC of 0.5 µg/mL, followed by Compound C at 2 µg/mL, Compound D at 4 µg/mL, and Compound A, with an MBC exceeding 4 µg/mL. Positive control plates showed unrestricted bacterial growth, confirming that growth inhibition was due solely to the AgNP treatment.
DISCUSSION/CONCLUSION: The results confirm that AgNPs possess strong in vitro bactericidal activity against P. aeruginosa, with efficacy varying by compound. Compound B demonstrated the greatest potential as an antimicrobial agent. These findings support the use of silver nanoparticles as a non-antibiotic treatment for multidrug-resistant bacterial infections. Determining the MBC is crucial for guiding potential therapeutic applications, ensuring maximum efficacy while minimizing cytotoxicity. Future studies should examine the effects of particle size, shape, and surface chemistry on antibacterial activity, as well as evaluate AgNP efficacy in vivo to fully assess their clinical potential.